Tissue Regenix Group PLC

Tissue Regenix Group PLC, also known as TRXG PLC, is a United Kingdom-based medical technology company. The company operated a manufacturing facility in the United States. Its core business involved the development and production of medical technologies, though specific products and served markets are not detailed in the provided information. The company's operational footprint included this American plant, representing its international manufacturing presence. No explicit details regarding the company's size, employee count, revenue, or precise market share are available. The organisation's structure, including ownership details or parent-subsidiary relationships, is not specified in the source material.

In January 2020, the company experienced a significant cybersecurity incident involving unauthorized access to its computer systems and those of a third-party IT provider located in the US. This breach prompted the temporary shutdown of its American manufacturing plant as a precautionary measure. The company responded by taking the affected systems offline and engaged forensic cybersecurity specialists alongside legal authorities to investigate the breach. The incident did not impact the company's United Kingdom operations or its financial systems. The cybersecurity event contributed to a significant decline in the company's share price. This breach occurred amid pre-existing concerns regarding the firm's funding stability beyond April of that year. No further details about the incident's technical specifics, data compromised, or long-term operational consequences beyond the plant shutdown are provided.